ArticleAlimentary pharmacology & therapeutics2022
Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study.
Article in Alimentary pharmacology & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 71 citations in OpenAlex.
- Chronic hepatitis D in Austria: high burden of cirrhosis and portal hypertension, IL28B C/C as unfavorable factor, increased systemic inflammation in decompensation.Wiener klinische Wochenschrift · 2026Article
- Correlation of Bile Acid Dynamics to Bulevirtide Response and Disease Severity in Patients With Hepatitis D.Alimentary pharmacology & therapeutics · 2026Article
- HERACLIS_BLV_D: Adherence to Real-Life Therapy With Bulevirtide in Chronic Hepatitis D.Journal of viral hepatitis · 2026Observational
- Response-guided bulevirtide ± pegylated interferon alfa-2a: Long-term outcomes observed in the nationwide Austrian hepatitis D cohort study.JHEP reports : innovation in hepatology · 2026Article
- Treatment response to bulevirtide is linked to amelioration of portal hypertension in patients with chronic hepatitis D.JHEP reports : innovation in hepatology · 2026Article
- Impact of Handling Perception and Language Barriers on Virologic Response to Daily Subcutaneous Bulevirtide in Hepatitis D.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- MUW researcher of the month.Wiener klinische Wochenschrift · 2025Article
- Observational
- Successful Amendment of an Existing Hepatitis B Screening Programme by a Guideline Recommended Hepatitis D Screening in the Primary Care Setting.Alimentary pharmacology & therapeutics · 2025Article
- Reflex testing for anti-HDV in HBsAg-positive patients offers high diagnostic yield in a large Central European tertiary care center.Scientific reports · 2024Article
- Molecular Epidemiology of Hepatitis D Virus in the North-East Region of Romania.Pathogens (Basel, Switzerland) · 2024Article
- Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide.JHEP reports : innovation in hepatology · 2024Article
- [Diagnosis and treatment of viral hepatitis B and D in 2024].Innere Medizin (Heidelberg, Germany) · 2024Review
- Prospects for Controlling Hepatitis B Globally.Pathogens (Basel, Switzerland) · 2024Review
- Management of chronic HBV-HDV patients chronic HBV-HDV infection: A review on new management options.United European gastroenterology journal · 2024Review
- Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations.JHEP reports : innovation in hepatology · 2024Article
- Current and future therapeutic options for chronic hepatitis D virus infection.Frontiers in cellular and infection microbiology · 2024Review
- [Delta hepatitis in Africa: epidemiological and clinical particularities].Medecine tropicale et sante internationale · 2023Review
- Hepatitis D Virus and HBsAg Dynamics in the era of new Antiviral Treatments.Current gastroenterology reports · 2023Review
- Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.Hepatology (Baltimore, Md.) · 2023Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
18 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimBulevirtide (BLV) blocks the uptake of the hepatitis D virus (HDV) into hepatocytes via the sodium/bile acid cotransporter NTCP. BLV was conditionally approved by the EMA but real-life data on BLV efficacy are limited.
methodsPatients were treated with BLV monotherapy. Patients who did not achieve further decreases in HDV-RNA after 24 weeks were offered PEG-IFN as an add-on therapy in a response-guided manner.
resultsTwenty-three patients (m: 10, f: 13; mean age: 47.9 years, cirrhosis: 16; median ALT: 71 IU/ml; median HDV-RNA: 2.1 × 10
conclusionLong-term BLV monotherapy is safe and effectively decreases HDV-RNA and ALT-even in patients with cirrhosis. The optimal duration of BLV treatment alone or in combination with PEG-IFN remains to be established. An algorithm for a response-guided BLV treatment approach is proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.